within Pharmacolibrary.Drugs.ATC.R;

model R05DB12
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.1,
    Cl             = 0.08333333333333333,
    adminDuration  = 600,
    adminMass      = 0.02,
    adminCount     = 1,
    Vd             = 0.0003,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Bibenzonium bromide is a quaternary ammonium compound classified as an antitussive, used for the treatment of cough. It acts as a peripheral antitussive agent, likely by suppressing the cough reflex through local action in the respiratory tract. It is not widely approved or currently used in most countries.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic data for bibenzonium bromide in humans was found. The following parameters are rough estimates based on related quaternary ammonium antitussives.</p><h4>References</h4><ol><li>Wolfgang LÃ¶scher, Pavel Klein,The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond.,CNS drugs,2021<a href='https://pubmed.ncbi.nlm.nih.gov/34145528/'>https://pubmed.ncbi.nlm.nih.gov/34145528/</a></li><li>A G Rauws,Pharmacokinetics of bromide ion--an overview.,Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association,1983<a href='https://pubmed.ncbi.nlm.nih.gov/6352432/'>https://pubmed.ncbi.nlm.nih.gov/6352432/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end R05DB12;
